A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 139, Issue 2, 2013, Pages 403-410

  Lin, N U ^a   Seah, D S ^a   Gelman, R ^a   Desantis, S ^a   Mayer, E L ^a   Isakoff, S ^b   Dipiro, P ^a   Krop, I E ^a   Come, S E ^c   Weckstein, D ^d   Winer, E P ^a   Burstein, H J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d New Hampshire Oncology Hematology PA   (United States)

Author keywords

Bevacizumab; Human epidermal growth factor receptor 2; Metastatic breast cancer; Trastuzumab; Vinorelbine

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; BACKACHE; BLEEDING DISORDER; BRAIN ISCHEMIA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPNEA; EPISTAXIS; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LIMB PAIN; LOADING DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; VOICE CHANGE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTOR, ERBB-2; TREATMENT OUTCOME; VINBLASTINE;

EID: 84878757223     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2551-9     Document Type: Article

References (17)

1. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
2. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
3. Burstein HJ, Kuter I, Campos SM et al (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730
4. Lin NU, Winer EP (2011) Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. J Clin Oncol 29:251-253
5. Burstein HJ, Harris LN, Marcom PK et al (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895
6. Burstein HJ, Keshaviah A, Baron AD et al (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110:965-972
7. Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29:264-271
8. Konecny GE, Meng YG, Untch M et al (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10:1706-1716
9. Pegram M, Chan D, Dichmann RA et al (2006) Phase II combined biological therapy targeting the HER-2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and avastin (B) as first-line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 100:abstr 301
10. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
11. Burstein HJ, Chen YH, Parker LM et al (2008) VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 14:7871-7877
12. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
13. Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286-4293
14. Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260
15. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247
16. Arteaga CL, Mayer IA, O'Neill AM et al (2012) A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu- overexpressing metastatic breast cancer (HER2 + MBC): A trial of the Eastern Cooperative Oncology Group (E1105). J Clin Oncol (suppl; abstr 605)
17. Gianni L, Romieu G, Lichinitser M et al (2011) AVEREL, a randomized phase III trial to evaluate bevacizumab in combination with trastuzumab + docetaxel as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. In: San Antonio Breast Cancer Symposium, TX, December 6-11, 2011